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ABSTRACT
Objective: In recent years increasing interest in the
issue of treatment personalization for type 2 diabetes
(T2DM) has emerged. This international web-based
survey aimed to evaluate opinions of physicians about
tailored therapeutic algorithms developed by the Italian
Association of Diabetologists (AMD) and available
online, and to get suggestions for future
developments. Another aim of this initiative was to
assess whether the online advertising and the survey
would have increased the global visibility of the AMD
algorithms.
Research design and methods: The web-based
survey, which comprised five questions, has been
available from the homepage of the web-version of the
journal Diabetes Care throughout the month of
December 2013, and on the AMD website between
December 2013 and September 2014. Participation
was totally free and responders were anonymous.
Results: Overall, 452 physicians (M=58.4%)
participated in the survey. Diabetologists accounted for
76.8% of responders. The results of the survey show
wide agreement (>90%) by participants on the utility
of the algorithms proposed, even if they do not cover
all possible needs of patients with T2DM for a
personalized therapeutic approach. In the online survey
period and in the months after its conclusion, a
relevant and durable increase in the number of unique
users who visited the websites was registered,
compared to the period preceding the survey.
Conclusions: Patients with T2DM are heterogeneous,
and there is interest toward accessible and easy to use
personalized therapeutic algorithms. Responders
opinions probably reflect the peculiar organization of
diabetes care in each country.
INTRODUCTION
In recent years, the increased availability of
pharmacological options has made the thera-
peutic management of type 2 diabetes
(T2DM) more complex and controversial,
prompting various scientific societies to
enact their own algorithms and guidelines.1–3
It is widely recognized that treatment goals
should be individualized on the basis of
patients’ characteristics.4 In addition,
although it is difficult to establish an overall
superiority of one agent over another in
terms of safety and efficacy, the possibility
exists that different drugs are more advisable
in specific subgroups of patients. The
concept of personalized management deci-
sions has consequently spread, in diabetology
as well as in other areas of medicine.
Nowadays, several scientific societies empha-
size the need for individualized and ‘patient-
centered’ approaches.1 5 6 At the same time,
a generic appeal to personalized therapy
risks to become a justification of empiricism,
unless some details are provided on the para-
meters leading to personalized choices.7
Since 2010, the Italian Association of
Diabetologists (Associazione Medici
Diabetologi, AMD) recognized the need to
develop personalized treatment plans for
people with T2DM. Among patients’
characteristics identified as possible determi-
nants of therapeutic choices, patients’ age,
presence of macrovascular diabetic complica-
tions or other comorbidities (ie, obesity,
renal failure or disabling conditions), occu-
pational risks potentially related to hypogly-
cemia, and the cognitive and nutritional
Key messages
▪ There is a clinical need for personalized algo-
rithms for patients with T2DM.
▪ This international survey aimed to evaluate opi-
nions of physicians about tailored therapeutic
algorithms developed by the Italian Association
of Diabetologists.
▪ The Italian algorithm for the treatment of T2DM
may improve the approach to a personalized
management of T2DM.
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status of the patient should be taken under active con-
sideration. These algorithms conceptual framework is
formed by the patients’ phenotyping, the personaliza-
tion of the objectives, a rational use of self-monitoring
blood glucose,8 as well as by the choice of drugs based
on phenotype and individual glycemic profiles. When
choosing an antidiabetic over another, the decision is
not guided only by criteria of effectiveness, but also by
pharmacodynamic properties, safety profile and
costs.9 10 From the beginning, the decision to favor web-
based over printed algorithms (borrowed from the
example of the Finnish guidelines, which have been
pioneer in this regard)5 6 aimed to offer a simple inter-
active tool, easy to use in daily clinical practice from
every PC connected to the web. AMD algorithms are
available online as a browser operated interactive tool, in
English and Italian.11 The reader can quickly locate the
phenotype of interest according to the patient’s clinical
features, and easily follow a step-by-step suggested addi-
tive therapeutic pathway.
Aware that these algorithms must be continuously
updated, AMD aims to acknowledge the latest data
arising from the evolution of scientific knowledge.
Nevertheless, the most important improvements can
only come from the critical contribution of all the physi-
cians who accept to test them in their daily clinical
routine, indicating their strengths and limitations.
For this reason, in December 2013 AMD led an initia-
tive of online advertising on the homepage of the web
version of the journal Diabetes Care. Through banner
advertising, readers from three continents (Europe,
North America and Asia) were invited to visit the
website of the algorithms, participating in an online
survey of a few minutes. The main objective of this
survey was to collect participants’ opinions on the actual
usefulness and critical issues of the algorithms, together
with their suggestions for future developments. Another
aim of this initiative was to assess whether the online
advertising and the survey would have increased the
global visibility of the website. This report presents the
results of this initiative.
MATERIALS AND METHODS
The web-based survey launched by AMD has been avail-
able from the homepage of the web-version of the
journal Diabetes Care (http://care.diabetesjournals.org)
throughout the month of December 2013. Furthermore,
the survey has been available on the AMD website
(http://www.aemmedi.it) between December 2013 and
September 2014. In Italy, this initiative was promoted
through email communications to all AMD members
and during the meetings of the scientific society.
Participation was totally free and responders were
anonymous. The survey included three sections:
1. A brief presentation of the AMD algorithms on the
personalized therapy for T2DM, with a clarification
on the rationale behind the proposals made and an
invitation to visit the website.
The presentation included the main purpose of
the online survey, that is, to know the participant
opinion on the algorithms, with the aim of assessing
their applicability in clinical practice and collecting
suggestions for their implementation.
2. Characteristics of responders: gender, age, Country,
specialty (ie, diabetologist/endocrinologist, general
practitioner (GP), etc) and number of patients with
T2DM seen in a typical month.
3. Participants’ opinions about the general usefulness of
algorithms dedicated to the treatment of diabetes,
the conceptual structure of the AMD algorithms and
their utility in the clinical practice.
In detail, five questions were posed to participants:
A. Do you think that computerized algorithms can be
useful in your clinical practice? (yes often/yes some-
times/not at all)
B. Do you think that the six main subcategories of
patients with T2DM identified by AMD algorithms
are correct? (yes/no)
C. Do you think that the phenotypization of patients
with T2DM according to the type and prevalence of
their blood sugar levels (fasting, preprandial, and
postprandial) can be relevant for choosing the most
appropriate antidiabetic therapy? (yes/no/i don’t
know)
D. What did you like most of the AMD algorithms?
(novelty/availability online/easy to use/complete-
ness/other)
E. Do you think that the algorithms are a useful tool
for: (GPs/diabetologist/endocrinologist/internists/
other specialties/none (multiple choice admitted))
Statistical analysis
Continuous data are expressed as mean±SD.
A stepwise multivariate logistic regression was applied
to identify physicians’ characteristics independently asso-
ciated with a positive opinion (‘Yes sometimes’ or ‘Yes
often’ vs ‘Not at all’) on the usefulness of algorithms in
clinical practice. Physician’s age, gender, specialty,
country of origin, and the number of patients with
T2DM seen in a typical month were inputed as
covariates.
All analyses were performed using SPSS V.20.0.
RESULTS
Characteristics of responders
Overall, 452 physicians (M=58.4%) participated in the
initiative. Of those, 40.7% were aged 40–55 years, and
48.5% were over 55 years. Diabetologists and endocrinol-
ogists accounted for 76.8% of responders, GPs for 8.4%,
whereas internists and other specialists for 14.8%
(figure 1). The great majority of responders were from
Italy (85.6%), but 75 participants were from other coun-
tries (mainly from Europe and from the USA, but also
from Far and Middle East Asia, Africa, Oceania, and the
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Caribbean). Most of the responders worked at a hospital
(79%), and 24.3% worked as private practitioners.
As to the number of type 2 patients with diabetes seen in
a typical month, 51.6% of the 364 responders to this
questions stated that they see 50–200 patients, whereas
45.6% see more than 200 patients with T2DM in a month.
Responders opinions
The algorithms were perceived as useful for one’s own
practice by 418 (92.5%) of responders (‘sometimes’ for
219 (48.5%) and ‘often’ for 199 (44%); figure 2A).
Responses about the algorithms were very positive irre-
spective of specialty, Country of origin, gender, age cat-
egory or number of patients seen in a typical month of
respondents.
Algorithms were considered useful for diabetes specia-
lists, GPs, and internists by 297 (65.7%), 254 (56.2%) and
166 (36.7%) of responders, respectively. Proportion of
positive responses were not significantly different for age
categories, gender or number of patients per month.
Conversely, a significantly (p<0.02) greater proportion of
Figure 1 Total respondents (N=452) divided according to
specialty practice, that is, diabetologists/endocrinologists
(N=347), other specialties (n=67) or general practitioner (n=38).
Figure 2 (A–E) Participants
answers to the questions of the
online survey.
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GPs, compared to diabetes specialists, considered the
algorithms useful for general practice, whereas algo-
rithms were considered useful for specialist practice by
diabetes specialists at a greater extent than by GPs
(p<0.01). Furthermore, responders from Italy were more
likely to consider the algorithms useful for diabetes spe-
cialists, whereas those from other countries found them
more useful for GPs (both p<0.01). In addition, a signifi-
cantly greater proportion of responders among those
aged more than 55 years than among those who were
younger found the algorithms useful for diabetes specia-
lists (p<0.01). For greater detail, see table 1.
At multivariate analysis (stepwise logistic regression),
profession and country of origin resulted independently
associated with the opinion about the usefulness of algo-
rithms for either GPs and diabetes specialists.
Responders from Italy perceived the algorithms more
useful for specialists and less useful for GPs, in compari-
son with participants from other countries, independent
of profession. In addition, in comparison with diabetes
specialists, GPs considered the algorithm more useful
for general practice, and less useful for specialists, inde-
pendent of country of origin (see table 2).
The vast majority (ie, 97.1%) of responders agreed
with the six main subcategories of patients with T2DM
identified by AMD algorithms (figure 2B). In addition,
89.9% believed that the phenotypization of patients with
T2DM according to their prevalent pattern of hypergly-
cemia (fasting, preprandial, and postprandial) is useful
for choosing the most appropriate antidiabetic therapy
(figure 2C).
With regard to the question “What did you like most of
the AMD algorithms?”, half of responders (50.9%) ranked
the simplicity of use in the first place (figure 2D).
Thirty-four (7.5%) of the responders considered the
algorithms useless; of those, 29 (85%) were diabetolo-
gists/endocrinologist, and the great majority of them
(28, ie, 82%) were from Italy.
Online visibility of the algorithms
In the online survey period and in the months after its
conclusion, we registered a significant increase in the
number of unique users who visited the websites of the
AMD algorithms (http://www.aemmedi.it/algoritmi_it_
2013 and http://www.aemmedi.it/algoritmi_en_2013/),
as well as in the number of page views of the algorithms,
and in the average time spent by visitors on algorithms
pages, compared to the period preceding the survey
(table 3). This increase concerned both Italian users
(with an increase of over 10 times of page views in a
month) and those from other countries (with an
increase of over 50 times). The increase in visitors,
number of pages and time spent on algorithms pages
was maintained for approximately 6 months after the
publication of the survey online, probably to an
increased interest promoted by the same survey.
DISCUSSION
In recent years there has been increasing interest in
the issue of treatment personalization, also in the
context of diabetes. Personalized medicine emphasizes
Table 1 Characteristics of participants who believe in the usefulness of the algorithms (n=418)
Age category Gender Country Patients monthly Practice
45–55 >55 Male Female Italy Others 50–200 >200 Hospital Private
Specialists diabetes/
endocrinology
(n=320) n (%)
161 (50) 159 (50) 186 (58) 134 (42) 294 (92) 26 (8) 168 (53) 152 (47) 276 (86) 44 (14)
General
practitioners (n=37)
n (%)
28 (75) 19 (25) 25 (67) 12 (33) 29 (78) 8 (22) 34 (92) 3 (8) NA
Others (n=61) n (%) 36 (59) 25 (41) 37 (60) 24 (40) 37 (60) 24 (40) 41 (67) 20 (33) 46 (75) 15 (25)
NA, not applicable.
Table 2 Characteristics of participants according to their opinion on the usefulness of the algorithms, at multivariate analysis
Characteristics
Useful for GPs Useful for diabetes specialists
OR (95% CI) p Value OR (95% CI) p Value
Country (Other vs Italy) 3.87 (1.94 to 7.72) <0.001 0.30 (0.17 to 0.55) <0.001
Profession
Diabetologist Ref. – Ref. –
GP 6.83 (2.12 to 22.03) 0.001 0.26 (0.11 to 0.64) 0.003
Other 0.95 (0.53 to 1.69) 0.86 1.48 (0.83 to 2.64) 0.18
GP, general practitioner.
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the customization of healthcare, with all decisions and
practices being tailored to individual patients whenever
possible.12 Its prerequisite is patient phenotyping, as well
as taking the realities of each individual patient’s circum-
stances into account. Its final aim is to optimize thera-
peutic responses, while improving tolerability and
compliance at the same time. It is noteworthy that, in
clinical practice, physicians feel more comfortable in
pursuing these goals when having pragmatic aids, such
as predefined algorithms, are available.13
Since 2010, the AMD algorithms have been reviewed
and updated three times. The last update in September
2014, as well as the previous one, was shared with the
Italian College of General Practitioners (SIMG, Italian
Society of General Medicine) in order to adopt a
common methodological approach during the medical
decision-making process, and included newly approved
drugs or expanded indications for existing ones in the
European Union.
The main purpose of this online survey was to collect
participants’ opinion on the AMD algorithms, to assess
their applicability in clinical practice and to get sugges-
tions for their implementation and for future versions.
The other aim of our initiative was to increase the visibil-
ity of the websites of the algorithms, especially for
non-Italian speaking users.
At our knowledge, this is the first online survey on a
web-based innovative personalized algorithm for the
treatment of T2DM. Although the results of the survey
show wide agreement by responders on the utility of the
algorithm proposed, we understand that it does not
cover all possible needs of patients with T2DM for a per-
sonalized treatment. This will be an incentive for
expanding the algorithm in the next future, taking into
account more different phenotypes such us patients with
previous cardiovascular events, gestational diabetes and
for approaching major cardiovascular risk factors asso-
ciated with T2DM such as arterial hypertension and dys-
lipidemia. Only thirty-four (7.5%) responders did not
find the algorithm of any utility, even if many of them
found it well designed or useful for GPs or specialists.
With regard to the number of responders, it must be
acknowledged that participation in the survey did not
provide any form of compensation, unlike many other
surveys received daily by each physician. The participa-
tion of Italian doctors, much higher than that of respon-
ders from other countries, could depend on a more
profound knowledge of the algorithms. The fact that
AMD repeatedly solicited via email the participation of
its members in the survey could be another explanation
for this finding. Furthermore, the advertising for Italian
physicians continued from December 2013 to
September 2014, while online advertising on the journal
home page lasted only a month.
The opinion of responders from Italy in perceiving the
algorithms more useful for specialists and less useful for
GPs, in comparison with participants from other countries,
may be the consequence of national peculiarities in the
organization of diabetes care. All Italian citizens, regard-
less of social class or income, are cared for by a general
practitioner as part of the National Health System. GPs
cooperate with a public network of about 700 diabetes out-
patient clinics in providing primary care for persons with
diabetes, which is completely free of charge.14–16 Italian
GPs can prescribe the most innovative drugs only on spe-
cialists’ authorization, and therefore, GPs who do not keep
in touch with diabetes care teams cannot autonomously
decide to use GLP-1 receptor agonists and DDP4 inhibi-
tors. Generally, GPs are more involved in earlier stages of
the natural history of diabetes, whereas diabetes specialists
concentrate most of their resources on inadequately con-
trolled, insulin-treated or complicated patients. For
example, insulin therapy is initiated by specialists in most
instances.17 On the other hand, current rules for reim-
bursement establish that ‘innovative’ drugs (which include
DPP4 inhibitors and GLP-1 receptor agonists) are pro-
vided free of charge only when prescribed by a certified
specialist. As a consequence, available therapeutic choices
for Italian GPs are limited to older drugs: this could
explain the perceived reduced usefulness of the algo-
rithms for this medical category. Conversely, in other coun-
tries, where all physicians have access to all therapies, GPs
could benefit from the use of algorithms more than dia-
betes specialists.
Limitations of the study must to be acknowledged.
The study design implies that the results of the survey
reflect the opinions of its participants; they could be sys-
tematically different from the opinions of non-
Table 3 Single accesses to the AMD algorithms websites
and average time on site before and after the online
advertising initiative (http://www.aemmedi.it/algoritmi_it_
2013/ and http://www.aemmedi.it/algoritmi_en_2013/)
Month
Unique
visitors
Page views Average
time on
siteItalian English
Oct 2013 836 1971 298 405200
Nov 2013 1235 4056 789 805600
Dec 2013
(advertising)
4726 6046 11 736 1202400
Jan 2014 8978 9897 14 054 1204400
Feb 2014 9912 17 613 16 827 1305600
Mar 2014 11 927 20 582 14 418 1402100
Apr 2014 9596 16 576 9026 1102700
May 2014 4467 11 347 1263 805600
Jun 2014 3189 10 921 854 602900
Jul 2014 2027 7625 1278 503100
Aug 2014 926 2398 981 400800
Sep 2014 1857 6538 258 404100
Oct 2014 2154 11 528 136 701700
Nov 2014 3127 10 327 318 800200
Dec 2014 2654 6428 278 501100
Jan 2015 1938 5238 326 402900
69 549 149 091 7284 801300
AMD, Italian Association of Diabetologists.
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responders. Nevertheless, the quite large number of
physicians involved from different countries seems
reassuring regarding the generalizability of the results.
One more limit to be considered is that the vast majority
of respondents are Italians and this could influence the
results. We also need to take into account that treatment
algorithms from other organizations are more extensive
than ours and this could represent a possible bias for
those respondents who have more familiarity with such
algorithms.
Patients with T2DM are heterogeneous in their clin-
ical features, and there is a clinical need for persona-
lized algorithms that cover several issues. In our view
tailored therapy is the best approach to optimize dia-
betes care, and the Italian algorithm for the treatment
of T2DM is an innovative, accessible and easy to use tool
for every day application and for every clinician who
manage patients with diabetes. Even if we are fully aware
that AMD algorithms cannot cover all of the possible
combinations encountered in daily clinical practice, we
hope that they may counteract clinical inertia, contribut-
ing, in a small way, to improve the approach to a perso-
nalized management of T2DM.
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